Vol 19, No 1 (2018)

Table of Contents

Letter to the Editor

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico
HTML PDF

Original research

Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Margherita Andretta, Silvio Borrè, Chiara Cattaruzzi, Gina Gasperini, Fabio Lena, Alessia Pisterna, Luca Degli Esposti
HTML PDF
Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Giovanni Gancitano, Roberto Ravasio, Matteo Dionisi, Diego Cortinovis
HTML PDF
Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model
Lorenzo Pradelli, Sara Villa, Giancarlo Castaman
HTML PDF
Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation
Marco Bellone, Lorenzo Pradelli, Mario Bo
HTML PDF

Focus On

Personalized medicine: biomarkers and companion diagnostics
Renato Bernardini, Giovanni Gancitano, Angela Balice, Rosaria Di Mauro, Giuseppina Cantarella, Matteo Dionisi
HTML PDF

Acknowledgement to reviewers

Acknowledgement to Reviewers (January - December 2018)
 
HTML PDF

Editorial Staff Disclosure

Editorial Staff Disclosure (2018)
 
HTML PDF